137 Startups
  • Sector
  • Participated in
  • Year of participation

Praxa Sense

  • 2019
  • Diagnostics
  • Venture Challenge
Easy & accurate long-term monitoring for Atrial Fibrillation. By providing unobtrusive, long-term monitoring and reliable diagnosis, Praxa Sense offers a solution to detect heart rhythm diseases in an early stage, preventing up to 9 strokes each day in The Netherlands alone.

Precision Immunomics

  • 2018
  • Diagnostics
  • Venture Challenge
We developed a test that accurately identifies patients that will develop rheumatoid arthritis within 3 years. Our mission is to substantially reduce the high burden of this disease by helping rheumatologists worldwide identify these high-risk patients in order to start preventive therapy.

PrecorDx

  • 2022
  • Diagnostics
  • Medical Device
  • Venture Challenge
PrecorDx develops a non-invasive diagnostic platform aimed at reducing hospital admissions and mortality in heart failure (19.5M patients in the USA and EU). This new diagnostic modality is based on the unique, novel Radio-Frequency Sensing (RFS) technology.

Predica Diagnostics

  • 2018
  • Diagnostics
  • Venture Challenge
Predica’s mission is to personalize the population based screening program cervical cancer and thereby prevent overdiagnosis and unnecessary treatment of healthy women who test positive in the current screening program.

Prolira

  • 2014
  • Diagnostics
  • Value Centre
  • Venture Challenge
Prolira provides the first proprietary and validated biomarker-based medical device to detect the onset of delirium, with a sensitivity of 90%. This enables health care professionals in realising better patient outcome, saving hospital days and reducing costs.

Protinhi

  • 2012
  • Other
  • Therapeutics
  • Venture Challenge
Combating viral infectious diseases with a high unmet medical need. Treating disease via protease inhibition.

Quirem Medical

  • 2012
  • 2016
  • Other
  • Therapeutics
  • Value Centre
Quirem Medical is an emerging medical device company with a mission to develop and commercialize the next generation microspheres for targeted interventional treatment of liver malignancies.

QurieGen

  • 2021
  • Enabling Technology
  • Venture Challenge
QurieGen provides quantitative information on the mode of action of drug molecules across multiple pathways over different timescales.

QVQ

  • 2011
  • Enabling Technology
  • Other
Labelled single domain antibodies from camelids (professionally called functionalized VHH) for Research and Imaging. 

River Biomedics

  • 2018
  • Enabling Technology
  • Venture Challenge
River BioMedics offers new human cardiac 3D models for target validation during drug discovery. Our 3D models are scalable to high-throughput and provide clinically relevant cardiac readouts for reliable drug efficacy validation.